SCIENCE & technologies
Transition's TT401 targets the GLP-1 receptor and a second therapeutic receptor, potentially providing better outcomes for type 2 diabetes and obese patients
The fastest growing segment of the diabetes therapeutic market is the glucagon-like-peptide-1 (GLP-1) agonist drug class. GLP-1 is a gut hormone secreted after meals and plays an important role in regulating blood glucose. Unlike conventional diabetes drugs, GLP-1 agonists provide effective glucose control in diabetes patients without the risk of hypo-glycemia. In addition, patients on GLP-1 therapy experience marginal weight loss, in contrast to some of the other diabetes drugs that cause weight gain.
Obesity is considered to be the primary cause of type 2 diabetes in people who are genetically predisposed to the disease. Thus, weight management is an important clinical objective for treating DM II patients as well as obese people.
TT401 is a GLP-1 dual agonist which targets both the GLP-1 and glucagon receptors. These receptors play integral roles in regulating appetite, food intake, satiety and energy utilization in the body.
Clinical Development
TT401 has been tested in a recent proof-of-concept study with 50 obese diabetic patients (five dose levels) as well as 10 non-diabetic obese patients (one dose level). During the study, patients received TT401 or placebo once weekly for five weeks.
• Proof-of-concept study completed (Apr 2013) - Link to press release
Key Findings from the Proof-of-Concept Study
• Three highest dose groups showed significant reduction in fasting plasma glucose relative to placebo • Significant body weight reduction from baseline in three highest dose groups • A similar reduction in body weight in the non-diabetic obese subjects • An acceptable safety and tolerability profile at all doses • Decreased appetite was the most common adverse event noted • Some subjects in the highest three dose groups experienced mild nausea and vomiting, which are
• consistent with studies of other GLP-1 agonist drug candidates
The fastest growing segment of the diabetes therapeutic market is the glucagon-like-peptide-1 (GLP-1) agonist drug class. GLP-1 is a gut hormone secreted after meals and plays an important role in regulating blood glucose. Unlike conventional diabetes drugs, GLP-1 agonists provide effective glucose control in diabetes patients without the risk of hypo-glycemia. In addition, patients on GLP-1 therapy experience marginal weight loss, in contrast to some of the other diabetes drugs that cause weight gain.
Obesity is considered to be the primary cause of type 2 diabetes in people who are genetically predisposed to the disease. Thus, weight management is an important clinical objective for treating DM II patients as well as obese people.
TT401 is a GLP-1 dual agonist which targets both the GLP-1 and glucagon receptors. These receptors play integral roles in regulating appetite, food intake, satiety and energy utilization in the body.
Clinical Development
TT401 has been tested in a recent proof-of-concept study with 50 obese diabetic patients (five dose levels) as well as 10 non-diabetic obese patients (one dose level). During the study, patients received TT401 or placebo once weekly for five weeks.
• Proof-of-concept study completed (Apr 2013) - Link to press release
Key Findings from the Proof-of-Concept Study
• Three highest dose groups showed significant reduction in fasting plasma glucose relative to placebo • Significant body weight reduction from baseline in three highest dose groups • A similar reduction in body weight in the non-diabetic obese subjects • An acceptable safety and tolerability profile at all doses • Decreased appetite was the most common adverse event noted • Some subjects in the highest three dose groups experienced mild nausea and vomiting, which are
• consistent with studies of other GLP-1 agonist drug candidates